Anesthesia
Conditions
Brief summary
The main purpose of this investigation is to collect safety and efficacy information of Eslax Intravenous 25mg/2.5mL and 50mg/5.0mL (hereinafter referred to as Eslax) in daily clinical settings.
Detailed description
Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.
Interventions
DRUGRocuronium
Normally, for adults, 0.6 mg/kg of rocuronium bromide is intravenously administered to support endotracheal intubation. If additional administration is necessary, 0.1 - 0.2 mg/kg is intravenously administered. In the case of continuous infusion, infusion is initiated at a rate of 7 μg/kg/min. Dosage should be adjusted based on the age or symptom. The upper limit of this drug for the intubation is 0.9 mg/kg.
Sponsors
Merck Sharp & Dohme LLC
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients to whom Eslax has been administered to relax muscles at the time of anesthesia or tracheal intubation.
Exclusion criteria
* Patients with a history of hypersensitivity to Eslax or bromide. * Patients with myasthenia gravis or myasthenic syndrome.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of adverse events | The standard observation period for a patient is duration of hospital stay (from one week before Eslax administration to one week after administration at a maximum). |
Secondary
| Measure | Time frame |
|---|---|
| intubation score | From administration of Eslax to completion of intubation |
| intubation completion time | From administration of Eslax to completion of intubation |
Outcome results
None listed